MAPK8 and chronic myelogenous leukemia, BCR-ABL1 positive: And although treatment with the tyrosine kinase inhibitor Imatinib (IM, first line treatment for CML) had no effect on the phosphorylation level of ERK, AKT, or JNK in CML-derived iPSCs, the phosphorylation of signal transducer and activator of transcription (STAT) 5 and V-srk avian sarcoma virus CT10 oncogene homolog-like (CRKL), often activated in CML cells, were significantly reduced.